10/29/2026
🚨 Autism Research Update: L1-79 is heading toward Phase-3!
If you’ve seen headlines about L1-79, an experimental autism medication, here’s what the research has shown, and what’s next 👇
In 2018, L1-79 received FDA Fast Track Designation for its development as a potential treatment for some of the core symptoms of autism. Now, Yamo Pharmaceuticals is planning to begin Phase 3 clinical trials in early 2027.
What is L1-79?
L1-79 is an investigational medication that inhibits tyrosine hydroxylase, an enzyme involved in producing dopamine and norepinephrine. Researchers are investigating whether this approach may improve social-interaction symptoms associated with autism.
What have we learned so far?
In 2024, in a Phase 2 study of 58 adolescents and young adults with autism, Yamo reported statistically significant improvements compared with placebo on the Vineland-3 Socialization score.
Additionally, a 2019 case series involving eight participants reported improvements on several behavioral and clinical assessments. However, the authors emphasized that controlled studies were needed to confirm these preliminary findings.
What’s next?
Yamo Pharmaceuticals plans to advance L1-79 into Phase 3 trials in early 2027 – an important next step in evaluating its safety and effectiveness.
Important: IL1-79 is investigational and is NOT FDA-approved. Earlier results are promising but do not establish that the medication is effective, which is exactly why these phase 3 trials will be so important for further evaluating its potential benefits and risks.
💙 Follow for more evidence-based updates on autism research and emerging clinical trials.
📚 Sources:
• Rothman et al., Clinical Therapeutics, 2019 – Eight-participant case series.
• Yamo Pharmaceuticals, July 2024 – Phase 2 results announcement.
• ClinicalTrials.gov: NCT05067582 – Phase 2 study details.
• Yamo Pharmaceuticals, October 2026 – Planned Phase 3 trial updates.
For study updates and family registration information, visit access.yamopharma.com.